Aptevo Therapeutics Inc. (APVO)
| Market Cap | 3.57M -24.0% |
| Revenue (ttm) | n/a |
| Net Income | -26.51M |
| EPS | -29.72 |
| Shares Out | 2.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,694 |
| Open | 1.360 |
| Previous Close | 1.360 |
| Day's Range | 1.310 - 1.386 |
| 52-Week Range | 1.253 - 28.440 |
| Beta | 1.68 |
| Analysts | n/a |
| Price Target | 25.50 (+1,802.99%) |
| Est. Earnings | Nov 13, 2026 |
About APVO
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute mye... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
The average 12-month stock price target for APVO is $25.5, which is an increase of 1,802.99% from the latest price.
News
Aptevo says 10 patients with AML advanced to allogeneic stem cell transplant
Aptevo Therapeutics (APVO) announced that ten patients with newly diagnosed acute myeloid leukemia, AML, have advanced to allogeneic stem cell transplant following treatment with mipletamig in combina...
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeu...
Aptevo Therapeutics advances trispecific candidate toward clinical development
Aptevo Therapeutics (APVO) announced progress in its next-generation trispecific programs. The Company is optimizing several trispecific candidates for reliable, scalable manufacturing, an essential s...
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human Testing Trispecifics Combine Three Complementary Cancer-Fighting Functions in O...
Aptevo AML data ‘highly encouraging,’ says Roth Capital
Roth Capital views Aptevo Therapeutics (APVO)’ acute myeloid leukemia data as “highly encouraging.” Aptevo reported a 93% clinical benefit rate, a 79% incomplete hematologic recovery, and a 64% comple...
Aptevo Therapeutics’ mipletamig triplet shows 93% benefit in leukemia
Aptevo Therapeutics (APVO) announced a 93% clinical benefit rate with its mipletamig triplet in evaluable frontline acute myeloid leukemia – AML – patients with TP53 mutations, one of the most…
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:...
Aptevo Therapeutics files to sell 6.44M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 6.44M shares of common stock. The company is not selling any…
Aptevo Therapeutics announces exercise of warrants, PIPE for $4.5M in proceeds
Aptevo Therapeutics (APVO) announced it has entered into warrant inducement letter agreements with certain holders of its existing common warrants, pursuant to which such holders have agreed to exerci...
Aptevo Therapeutics reports $9.8M in cash, cash equivalents as of June 30
“During the second quarter, we made important progress against the programs and initiatives we believe can create near- and long-term value for Aptevo,” said Jeff Lamothe, President and Chief Executiv...
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non-Dilutive Grant...
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
SEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncol...
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
SEATTLE, WA / ACCESS Newswire / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncol...
Aptevo files patent application for Nectin-4 x PD-L1 dual-targeting backbone
Aptevo Therapeutics (APVO) announced a new solid tumor strategy designed to fight cancer on multiple fronts. The Company has filed a patent application covering a proprietary Nectin-4 x PD-L1 dual-tar...
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach SEATTLE, WA / ACCESS Newswire / July 27, 2026 / Apt...
Aptevo Therapeutics awarded $1.5M research grant from Andy Hill CARE Fund
Aptevo Therapeutics (APVO) announced it has been awarded a $1.5M non-dilutive research grant from the Andy Hill Cancer Research Endowment, CARE, Fund under its Implementation and Outcomes Research pro...
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
SEATTLE, WA / ACCESS Newswire / June 30, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary AD...
Aptevo Therapeutics appoints Janatpour as SVP, CSO
Aptevo Therapeutics (APVO) announced the appointment of Mary Janatpour, Ph.D., as Senior Vice President, SVP, and Chief Scientific Officer, CSO. Dr. Janatpour brings more than 25 years of oncology res...
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D.
Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy SEATTLE, WA / ACCESS Newswire / May 28, 2026 / Aptevo Therape...
Aptevo, Niowave launch collab for radiopharmaceutical oncology programs
Aptevo Therapeutics (APVO) and Niowave announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. Niowave made an at-the-market equity investment in Aptevo...
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI / A...
Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M
“Aptevo is entering a defining period as a company, supported by growing clinical momentum, a committed leadership team, and a pipeline with the potential to create significant long-term value,” said…
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patients Executive leadership transition complete. Jeff Lamothe appointed CE...
Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial
Aptevo Therapeutics (APVO) reported new clinical results from its RAINIER frontline acute myeloid leukemia trial. The company is on track to complete the Phase 1b dose-optimization trial and select th...
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Program Enters Final Stage of Dose Optimization Data Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6, ...